Senologie - Zeitschrift für Mammadiagnostik und -therapie 2014; 11 - A69
DOI: 10.1055/s-0034-1375428

Interim analysis of the early cosmetic outcome in the IMRT-MC2-trial

D Krug 1, V Askoxylaxis 1, J Heil 2, MF Häfner 1, H Hauswald 1, H Hof 3, A Zabel-du Bois 1, J Debus 1
  • 1Universitätsklinikum Heidelberg, Radioonkologie und Strahlentherapie, Heidelberg, Deutschland
  • 2Universitätsklinikum Heidelberg, Frauenklinik, Heidelberg, Deutschland
  • 3Strahlentherapie Rheinpfalz, Neustadt, Deutschland

Cosmetic results have a significant impact on quality of life in breast cancer survivors. Several trials have shown that simple forward-planned intensity-modulated radiotherapy can improve cosmetic results in terms of global cosmetic outcome, reduced hyperpigmentation and a reduced risk of moist desquamation.

The IMRT-MC2-trial is a phase III-randomized controlled trial comparing 3D-conformal radiotherapy with a sequential boost to inverse-planned intensity-modulated radiotherapy with a simultaneous integrated boost.

Patients with breast cancer after breast-conserving surgery were randomized to 3D-conformal radiotherapy of the whole breast up to 50,4 Gy followed by a boost of 16 Gy in 36 fractions or IMRT of the whole breast up to 50,4 Gy with a simultaneous-integrated boost up to 64,4 Gy in 28 fractions. Primary endpoints are locoregional control and cosmetic outcome. For this interim analysis, the first 109 patients were selected from the study database. The cosmetic outcome on standardized patient photographs before and 6 weeks after treatment was analyzed with the BCCT.core-Software.

There were no significant differences in BRA, pBRA and global cosmetic score as determined by the BCCT.core-Software at baseline and 6 weeks after treatment. There was a significant decline in global cosmetic outcome and pBRA in both groups.

In this unplanned interim analysis of a large randomized phase III-trial, IMRT with a simultaneous integrated boost yielded similar cosmetic results compared to 3D-conformal radiotherapy with sequential boost after breast-conserving surgery for breast cancer.